Calcitonin

Results: 99



#Item
31FINANCIAL REPORT JUNE[removed]EXPENDITURES PERSONNEL BENEFITS IN STATE TRAVEL

FINANCIAL REPORT JUNE[removed]EXPENDITURES PERSONNEL BENEFITS IN STATE TRAVEL

Add to Reading List

Source URL: reab.state.al.us

Language: English - Date: 2014-09-23 15:51:53
32Background Document: Cancer Public Meeting

Background Document: Cancer Public Meeting

Add to Reading List

Source URL: www.fda.gov

Language: English
33Calcitonin Salmon for the Treatment of Postmenopausal Osteoporosis Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee March 5, 2013

Calcitonin Salmon for the Treatment of Postmenopausal Osteoporosis Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee March 5, 2013

Add to Reading List

Source URL: www.fda.gov

Language: English
34Microsoft PowerPoint - Miacalcin_(calcitonin_salmon)_FINAL_3[removed]

Microsoft PowerPoint - Miacalcin_(calcitonin_salmon)_FINAL_3[removed]

Add to Reading List

Source URL: www.fda.gov

Language: English
35A broad range of markers including specialty assays: Calcitonin, TK, TPA, NSE, S100 Oncology

A broad range of markers including specialty assays: Calcitonin, TK, TPA, NSE, S100 Oncology

Add to Reading List

Source URL: www.diasorin.com

Language: English - Date: 2014-05-07 10:12:51
362014 PLENARY SPEAKERS Plenary Session I– Sunday, June 22, 2014 Dr. Ting-Kai Li Lectureship Karl Mann, M.D., Ph.D Karl Mann received his MD from Mainz University and his PhD from Tuebingen University. He is a board cert

2014 PLENARY SPEAKERS Plenary Session I– Sunday, June 22, 2014 Dr. Ting-Kai Li Lectureship Karl Mann, M.D., Ph.D Karl Mann received his MD from Mainz University and his PhD from Tuebingen University. He is a board cert

Add to Reading List

Source URL: rsoa.org

Language: English - Date: 2014-03-27 23:41:11
37News Release FOR  IMMEDIATE  RELEASE Contact:  Ronald C. Trahan, APR, Ronald Trahan Associates Inc., ([removed], x108 VasoGenix Pharmaceuticals selects a lead CGRP (calcitonin gene-related peptide) agonist anal

News Release FOR  IMMEDIATE  RELEASE Contact:  Ronald C. Trahan, APR, Ronald Trahan Associates Inc., ([removed], x108 VasoGenix Pharmaceuticals selects a lead CGRP (calcitonin gene-related peptide) agonist anal

Add to Reading List

Source URL: wichitatechnology.com

Language: English - Date: 2009-04-13 11:54:06
38News Release FOR  IMMEDIATE  RELEASE Contact:  Ronald C. Trahan, APR, Ronald Trahan Associates Inc., ([removed], x108 VasoGenix Pharmaceuticals elects Cleveland Clinic’s James Young, M.D., to its board of dir

News Release FOR  IMMEDIATE  RELEASE Contact:  Ronald C. Trahan, APR, Ronald Trahan Associates Inc., ([removed], x108 VasoGenix Pharmaceuticals elects Cleveland Clinic’s James Young, M.D., to its board of dir

Add to Reading List

Source URL: wichitatechnology.com

Language: English - Date: 2009-05-21 12:27:13
39U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
40HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FORTICAL® safely and effectively. See full prescribing information for FORTICAL.  ------------------------CONTRAIND

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FORTICAL® safely and effectively. See full prescribing information for FORTICAL. ------------------------CONTRAIND

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-07-11 13:41:13